Bio-Path price target lowered to $9 from $12 at Roth MKM

Roth MKM lowered the firm’s price target on Bio-Path (BPTH) to $9 from $12 and keeps a Buy rating on the shares. The company ended Q4 with $1.2M in cash, indicating Bio-Path requires near-term financing, the analyst tells investors. Additionally, there were no material pipeline updates in its quarterly earnings beyond those released last month, the firm adds.